4//SEC Filing
Wilson Mark Andrew 4
Accession 0000950170-24-140591
CIK 0000906709other
Filed
Dec 25, 7:00 PM ET
Accepted
Dec 26, 7:04 PM ET
Size
7.5 KB
Accession
0000950170-24-140591
Insider Transaction Report
Form 4
Wilson Mark Andrew
Chief Legal Officer
Transactions
- Sale
Common Stock
2024-12-23$0.90/sh−33,402$30,062→ 351,892 total - Sale
Common Stock
2024-12-24$0.89/sh−16,560$14,738→ 335,332 total
Footnotes (4)
- [F1]Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
- [F2]This transaction was executed in multiple trades at prices ranging from $.87 to $.91 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
- [F3]This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).
- [F4]This transaction was executed in multiple trades at prices ranging from $.89 to $.90 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001808356
Filing Metadata
- Form type
- 4
- Filed
- Dec 25, 7:00 PM ET
- Accepted
- Dec 26, 7:04 PM ET
- Size
- 7.5 KB